Woondong Jeong

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer

David E. Gerber, D. Ross Camidge, Daniel Morgensztern et al. · Lung Cancer · 2019 · 173 citations · Full text

Tumor Biology, Medicine, Cancer Biology +7

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

Woondong Jeong, Annamaria Rapisarda, Sook Ryun Park et al. · Cancer Chemotherapy and Pharmacology · 2013 · 149 citations · Full text

Hypoxia-inducible Factor-1 Alpha, Oncology, Malignant Disease +10

Phase 1 dose‐escalation study of mirvetuximab soravtansine (<scp>IMGN853</scp>), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors

Kathleen N. Moore, Hossein Borghaei, David M. O’Malley et al. · Cancer · 2017 · 133 citations · Full text

Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors

T. Khanh, Giovanna Speranza, Lun‐Ching Chang et al. · Investigational New Drugs · 2015 · 51 citations · Full text

Inhibitor Onalespib, Medicine, Pharmacology +8

Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors

Woondong Jeong, Sook Ryun Park, Annamaria Rapisarda et al. · Investigational New Drugs · 2013 · 27 citations · Full text

Weekly Ezn-2208, Medicine, Immunology +8